Patent application number | Description | Published |
20080280318 | Isolation and Culture of a High Purity Population of Cone Photoreceptor Cells by Tissue Dissociation and Pna-Panning, and Biological Applications Thereof - The present invention provides a process and kit for isolating cone photoreceptor cells from retinal tissue with a purity level of at least 80%, typically of about 90%. The isolation process uses a PNA-panning procedure conducted on dissociated retinal tissue. The present invention also provides a culture medium enabling the in vitro survival and development of such isolated cone cells. The means of the invention are applicable to adult mammalian cone cells, and more particularly to adult human cone cells. They have the advantage of being applicable to pathologic or otherwise altered cone cells, and thus give access to the screening of compounds capable of showing neuroprotective activity on adult cone cells. | 11-13-2008 |
20090292021 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed. | 11-26-2009 |
20100062987 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance. | 03-11-2010 |
20100184707 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation. | 07-22-2010 |
20120196281 | FUNCTIONALIZED ORGANOTYPIC SYSTEMS - The present invention provides an organotypic system comprising a portion of a retina containing live cells in a cultured in medium, wherein photosensitivity has been restored in at least some of said live cells. Methods of use thereof are also provided. | 08-02-2012 |
20130023986 | ARTIFICIAL RETINA THAT INCLUDES A PHOTOVOLTAIC MATERIAL LAYER INCLUDING A TITANIUM DIOXIDE SEMICONDUCTOR - An artificial retina that includes: (i) a substrate; (ii) a first layer, placed onto said substrate and including photovoltaic material portions separated by at least one insulating material portion; and (iii) a second layer, placed onto said first layer and including conductive material portions separated by at least one insulating material portion. In said artificial retina, the photovoltaic material includes a titanium dioxide semiconductor. | 01-24-2013 |
20130096660 | IMPLANT HAVING THREE-DIMENSIONAL SHAPE FOR ELECTRICALLY STIMULATING A NERVE STRUCTURE - The invention relates to an implant which includes, in order to electrically stimulate a nerve structure, in particular the retina, an electrically insulating substrate ( | 04-18-2013 |
20140300857 | OPHTHALMIC FILTER - An optical device including: an optical substrate provided with selective optical filtering element configured to selectively inhibit transmission, through the optical substrate of at least one selected range of wavelengths of incident light in the visible light spectrum at an inhibition rate of at least 5%, the selective optical filtering element being further configured to transmit at least 8% of incident light of the visible spectrum outside the at least one selected range of wavelengths; wherein the at least one selected range of wavelengths has a bandwidth in a range of from 10 nm to 70 nm, preferably 10 nm to 60 nm centered on a wavelength within a range of between 430 nm and 465 nm. | 10-09-2014 |
20140320806 | METHOD OF DETERMINING THE CONFIGURATION OF AN OPHTHALMIC FILTER - Method of determining configuration of interferential filtering elements for an optical device having an optical substrate for a user, includes:
| 10-30-2014 |
Patent application number | Description | Published |
20110172171 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION OF BRAIN OEDEMA - The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention of brain oedema. | 07-14-2011 |
20110183890 | METHODS FOR MODULATING ANGIOGENESIS VIA DYSTROPHIN DP71 - The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject. | 07-28-2011 |
20120027723 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION - The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. | 02-02-2012 |
20120157532 | Method Of Treating Or Preventing A Convulsive Disorder In A Patient In Need Thereof - The present invention relates to a method of treating or preventing a convulsive disorder in a patient in need thereof comprising administering said patient with a therapeutically effective amount of an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation once per day in the evening or at night. | 06-21-2012 |
20150038557 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES - The present invention relates to an isolated nucleic acid molecule comprising i) a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence and ii) a nucleotide sequence coding for a neurotrophic factor for use in the treatment of a retinal degenerative disease. | 02-05-2015 |